Pheochromocytoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
*Most catecholamine-secreting tumors are sporadic. | *Most catecholamine-secreting tumors are sporadic. | ||
*However, 30% of patients got the tumor as a part of the familial disease, the catecholamine-secreting tumors are more likely to be bilateral.<ref name="pmid28324046">{{cite journal| author=Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM et al.| title=Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. | journal=J Clin Endocrinol Metab | year= 2017 | volume= 102 | issue= 4 | pages= 1122-1132 | pmid=28324046 | doi=10.1210/jc.2016-3829 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28324046 }}</ref> | *However, 30% of patients got the tumor as a part of the familial disease, the catecholamine-secreting tumors are more likely to be bilateral.<ref name="pmid28324046">{{cite journal| author=Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM et al.| title=Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas. | journal=J Clin Endocrinol Metab | year= 2017 | volume= 102 | issue= 4 | pages= 1122-1132 | pmid=28324046 | doi=10.1210/jc.2016-3829 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28324046 }}</ref> | ||
Symptoms start with tachycardia, hypertension, headache and sweating. If left untreated it causes hyperglycemia, [[Hypertensive Emergencies|hypertension emergency]] that causes heart failure, [[Stroke|cerebrovascular strokes]]. If malignant, It can metastasize to [[lymph nodes]], [[bones]], [[lungs]], and [[liver]]. | Symptoms start with tachycardia, hypertension, headache, and sweating. If left untreated it causes hyperglycemia, [[Hypertensive Emergencies|hypertension emergency]] that causes heart failure, [[Stroke|cerebrovascular strokes]]. If malignant, It can metastasize to [[lymph nodes]], [[bones]], [[lungs]], and [[liver]]. | ||
===Complication=== | ===Complication=== | ||
| Line 17: | Line 17: | ||
Other complications may include: | Other complications may include: | ||
*[[Hyperglycemia]] due to opposing insulin effect by high doses of adrenaline secreted by the tumor. | *[[Hyperglycemia]] due to opposing insulin effect by high doses of adrenaline secreted by the tumor. | ||
*[[Malignant hypertension]] that may cause cerebrovascular accidents such as intracranial hemorrhage, coronary syndrome, aortic dissection and heart failure. | *[[Malignant hypertension]] that may cause cerebrovascular accidents such as [[intracranial hemorrhage]], coronary syndrome, [[aortic dissection]] and heart failure. | ||
*[[Metastasis]] to [[lymph nodes]], [[bones]], [[lungs]], and [[liver]]. | *[[Metastasis]] to [[lymph nodes]], [[bones]], [[lungs]], and [[liver]]. | ||
===Prognosis=== | ===Prognosis=== | ||
* Pheochromocytoma prognosis is good if treated. | * Pheochromocytoma prognosis is good if treated. | ||
* Approximately 10% recur after being resected. | * Approximately 10% recur after being resected. | ||
* Patients with metastatic pheochromocytoma five-year survival rates are approximately 50%.<ref name="cancergov" />Survival rate may depend on the primary tumor site and sites of metastases. | * Patients with metastatic pheochromocytoma five-year survival rates are approximately 50%.<ref name="cancergov" />Survival rate may depend on the primary tumor site and sites of [[Metastasis|metastases]]. | ||
* Tumor burden, the location of metastases, and rate of progression are the main factors affecting prognosis. Metastases in the brain, the liver has a worse prognosis than other metastases. | * Tumor burden, the location of metastases, and rate of progression are the main factors affecting prognosis[[Metastasis|. Metastases]] in the brain, the liver has a worse prognosis than other metastases. | ||
* '''Prognosis of surgery''' | * '''Prognosis of surgery''' | ||
**Good prognosis patients include small tumor size, short duration of surgery, systolic blood pressure less than 160 mmHg, and low levels of urinary catecholamines.<ref name="pmid20336320">{{cite journal| author=Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC et al.| title=Trends in adrenalectomy: a recent national review. | journal=Surg Endosc | year= 2010 | volume= 24 | issue= 10 | pages= 2518-26 | pmid=20336320 | doi=10.1007/s00464-010-0996-z | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20336320 }}</ref> | **Good prognosis patients include small tumor size, short duration of surgery, [[systolic blood pressure]] less than 160 mmHg, and low levels of urinary [[catecholamines]].<ref name="pmid20336320">{{cite journal| author=Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC et al.| title=Trends in adrenalectomy: a recent national review. | journal=Surg Endosc | year= 2010 | volume= 24 | issue= 10 | pages= 2518-26 | pmid=20336320 | doi=10.1007/s00464-010-0996-z | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20336320 }}</ref> | ||
**Postoperative hypotension can be avoided by adequate fluid replacement. | **Postoperative hypotension can be avoided by adequate fluid replacement. | ||
**Recurrence is more in patients with familial pheochromocytoma and extra-adrenal tumors.<ref name="pmid11297571">{{cite journal| author=Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G| title=Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. | journal=J Clin Endocrinol Metab | year= 2001 | volume= 86 | issue= 4 | pages= 1480-6 | pmid=11297571 | doi=10.1210/jcem.86.4.7392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11297571 }}</ref> | **Recurrence is more in patients with familial pheochromocytoma and extra-adrenal tumors.<ref name="pmid11297571">{{cite journal| author=Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G| title=Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. | journal=J Clin Endocrinol Metab | year= 2001 | volume= 86 | issue= 4 | pages= 1480-6 | pmid=11297571 | doi=10.1210/jcem.86.4.7392 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11297571 }}</ref> | ||
**Familial pheochromocytomas have a high incidence of bilateral disease. | **Familial pheochromocytomas have a high incidence of bilateral disease. | ||
**Partial [[adrenalectomy]] is recommended for these patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency. | **Partial [[adrenalectomy]] is recommended for these patients with bilateral pheochromocytomas to prevent permanent [[glucocorticoid]] deficiency. | ||
**Complete bilateral [[adrenalectomy]] is recommended for MEN2 patients. There is a high rate of recurrence than in sporadic cases. Follow up for a long duration after surgery is needed. Most patients should have annual biochemical screening. | **Complete bilateral [[adrenalectomy]] is recommended for [[Multiple endocrine neoplasia type 2|MEN2]] patients. There is a high rate of recurrence than in sporadic cases. Follow up for a long duration after surgery is needed. Most patients should have annual biochemical screening. | ||
==References== | ==References== | ||
Revision as of 13:05, 15 August 2017
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma natural history, complications and prognosis |
|
FDA on Pheochromocytoma natural history, complications and prognosis |
|
CDC on Pheochromocytoma natural history, complications and prognosis |
|
Pheochromocytoma natural history, complications and prognosis in the news |
|
Blogs on Pheochromocytoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Pheochromocytoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]
Overview
Pheochromocytoma is an adrenaline secreting tumor, usually develop in the fifth decade of life. Symptoms start with tachycardia, hypertension, headache and sweating. Massive release of catecholamines can cause hyperglycemia, malignant hypertension and metastasis. The prognosis of pheochromocytoma is generally good but metastatic pheochromocytoma has a 5-year survival rate of approximately 50%[1]
Natural History, Complications and Prognosis
Natural History
- Pheochromocytoma is the adrenaline secreting tumor, usually develop in the fifth decade of life.
- Fifty percent of pheochromocytomas in children are solitary intra-adrenal lesions, 25% are present bilaterally, and 25% are extra-adrenal.
- Most catecholamine-secreting tumors are sporadic.
- However, 30% of patients got the tumor as a part of the familial disease, the catecholamine-secreting tumors are more likely to be bilateral.[2]
Symptoms start with tachycardia, hypertension, headache, and sweating. If left untreated it causes hyperglycemia, hypertension emergency that causes heart failure, cerebrovascular strokes. If malignant, It can metastasize to lymph nodes, bones, lungs, and liver.
Complication
- The massive release of catecholamines in pheochromocytoma can cause damage to myocytes.[3] This damage may be due to either a compromise of the coronary microcirculation or the direct toxic effects of catecholamines on myocytes.[3]
Other complications may include:
- Hyperglycemia due to opposing insulin effect by high doses of adrenaline secreted by the tumor.
- Malignant hypertension that may cause cerebrovascular accidents such as intracranial hemorrhage, coronary syndrome, aortic dissection and heart failure.
- Metastasis to lymph nodes, bones, lungs, and liver.
Prognosis
- Pheochromocytoma prognosis is good if treated.
- Approximately 10% recur after being resected.
- Patients with metastatic pheochromocytoma five-year survival rates are approximately 50%.[1]Survival rate may depend on the primary tumor site and sites of metastases.
- Tumor burden, the location of metastases, and rate of progression are the main factors affecting prognosis. Metastases in the brain, the liver has a worse prognosis than other metastases.
- Prognosis of surgery
- Good prognosis patients include small tumor size, short duration of surgery, systolic blood pressure less than 160 mmHg, and low levels of urinary catecholamines.[4]
- Postoperative hypotension can be avoided by adequate fluid replacement.
- Recurrence is more in patients with familial pheochromocytoma and extra-adrenal tumors.[5]
- Familial pheochromocytomas have a high incidence of bilateral disease.
- Partial adrenalectomy is recommended for these patients with bilateral pheochromocytomas to prevent permanent glucocorticoid deficiency.
- Complete bilateral adrenalectomy is recommended for MEN2 patients. There is a high rate of recurrence than in sporadic cases. Follow up for a long duration after surgery is needed. Most patients should have annual biochemical screening.
References
- ↑ 1.0 1.1 National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc
- ↑ Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM; et al. (2017). "Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas". J Clin Endocrinol Metab. 102 (4): 1122–1132. doi:10.1210/jc.2016-3829. PMID 28324046.
- ↑ 3.0 3.1 Goldman 2011, pp. 327
- ↑ Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC; et al. (2010). "Trends in adrenalectomy: a recent national review". Surg Endosc. 24 (10): 2518–26. doi:10.1007/s00464-010-0996-z. PMID 20336320.
- ↑ Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G (2001). "Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center". J Clin Endocrinol Metab. 86 (4): 1480–6. doi:10.1210/jcem.86.4.7392. PMID 11297571.